Evidence — KPV
peptide · asset evidence level: emerging
Evidence quality breakdown (linked documents)
expert_opinion: 4preclinical: 1
Linked source documents (5)
- Integrative Peptide Therapy — Clinical Reference Protocol (Demo Import) (physician_protocol · expert_opinion)
- Copy of Synergistic Effects of Monolaurin, Thymosin Alpha-1, KPV, SS-31, MOTS-c, Zinc, Vitamin D3, B12, Folate, Selenium, Magnesium Glycinate, and DGL on Epstein-Barr Virus Reversal in a Murine Gammaherpesvirus 68 (MHV-68) Model.docx (physician_protocol · expert_opinion)
- Synergistic Effects of BPC-157, KPV, Thymosin Alpha-1, GHK-Cu, and Targeted Nutritional Cofactors on Bell’s Palsy Reversal in a Facial Nerve Crush Murine Model.docx (physician_protocol · expert_opinion)
- Synergistic Effects of Monolaurin, Thymosin Alpha-1, KPV, SS-31, MOTS-c, Zinc, Vitamin D3, B12, Folate, Selenium, Magnesium Glycinate, and DGL on Epstein-Barr Virus Reversal in a Murine Gammaherpesvirus 68 (MHV-68) Model.docx (physician_protocol · expert_opinion)
- KPV: Mechanistic Overview (internal_protocol · preclinical)
Provider dosing references (Stage 9, source-attributed)
200-500 mcg SC daily, or 250-500 mcg orally twice daily for gut-directed support — Practitioner Peptide Dosing Reference (commonly published ranges)
Dosing claims (27) · Safety claims (9)
Extracted claims are provider-review scaffolding, stored verbatim with source attribution — not recommendations or dosing guidance.